Deep Brain Stimulation in Parkinson’s Disease

Global Deep Brain Stimulation in Parkinson’s Disease Market to Reach US$1.5 Billion by 2030

The global market for Deep Brain Stimulation in Parkinson’s Disease estimated at US$882.5 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Dual-Channel Deep Brain Stimulation, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$953.8 Million by the end of the analysis period. Growth in the Single-Channel Deep Brain Stimulation segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$240.4 Million While China is Forecast to Grow at 13.8% CAGR

The Deep Brain Stimulation in Parkinson’s Disease market in the U.S. is estimated at US$240.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$322.2 Million by the year 2030 trailing a CAGR of 13.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Deep Brain Stimulation in Parkinson’s Disease Market – Key Trends & Drivers Summarized

Is Deep Brain Stimulation the Future of Parkinson’s Disease Treatment?

Deep Brain Stimulation (DBS) has emerged as a groundbreaking treatment for Parkinson’s disease, offering new hope to patients experiencing motor fluctuations and medication-resistant symptoms. This neurosurgical procedure involves implanting electrodes into specific brain regions, delivering controlled electrical impulses to modulate abnormal neural activity. Over the years, DBS technology has significantly evolved, with newer, more precise systems improving patient outcomes. Traditional pharmacological treatments for Parkinson’s disease, such as levodopa, often become less effective over time, leading to debilitating motor complications. DBS provides a long-term solution, reducing tremors, rigidity, and dyskinesia, thereby improving quality of life. The rise in minimally invasive surgical techniques and real-time neuroimaging has enhanced the safety and accuracy of DBS procedures. Additionally, research into adaptive DBS, which adjusts stimulation levels dynamically based on brain activity, is opening new doors for personalized treatment strategies.

How Are Technological Advancements Enhancing Deep Brain Stimulation?

Advancements in DBS technology have dramatically improved precision, safety, and patient comfort. The introduction of rechargeable and MRI-compatible implants has increased the longevity of devices, reducing the need for frequent replacements. Closed-loop DBS systems, which adjust stimulation parameters in real time based on neural feedback, are revolutionizing the field by providing more tailored and efficient treatment. Furthermore, AI and machine learning are being integrated into DBS programming, allowing physicians to optimize stimulation settings with unprecedented accuracy. The emergence of wireless programming and remote monitoring capabilities is also making post-surgical management more efficient, enabling neurologists to track patient progress without requiring frequent hospital visits. These advancements are not only enhancing clinical outcomes but also expanding the accessibility of DBS to a broader patient base.

What Is Driving the Growing Adoption of DBS in Parkinson’s Patients?

The increasing prevalence of Parkinson’s disease, coupled with an aging global population, is driving the demand for advanced treatment options like DBS. As more clinical trials validate the long-term efficacy and safety of DBS, physicians are recommending the procedure earlier in disease progression rather than as a last-resort treatment. The growing awareness among patients about non-pharmacological interventions has also contributed to higher adoption rates. Additionally, improvements in surgical robotics and electrode placement techniques have reduced the risks associated with the procedure, making it a more viable option for a wider range of patients. Governments and healthcare organizations are also recognizing the benefits of DBS, leading to increased insurance coverage and reimbursement policies that make the treatment more financially accessible.

The Growth in the Deep Brain Stimulation in Parkinson’s Disease Market Is Driven by Several Factors…

The growth in the DBS market is driven by several factors, including rapid technological advancements, the rising incidence of Parkinson’s disease, and an increasing preference for non-invasive, long-term treatment solutions. The development of AI-driven and closed-loop stimulation systems is enhancing treatment precision, making DBS more effective for a broader range of patients. The expansion of neurology-focused healthcare infrastructure and increasing investments in neurotechnology research are also playing a crucial role in market expansion. Furthermore, the rising number of regulatory approvals and favorable reimbursement policies are encouraging more hospitals and clinics to adopt DBS as a standard Parkinson’s treatment. The push toward personalized medicine, where stimulation parameters are adjusted based on patient-specific needs, is another major driver propelling the market forward.

SCOPE OF STUDY:

The report analyzes the Deep Brain Stimulation in Parkinson’s Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Dual-Channel Deep Brain Stimulation, Single-Channel Deep Brain Stimulation); End-Use (Hospitals End-Use, Ambulatory Surgical Centers End-Use, Neurology Clinics End-Use, Research Centers End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Abbott Laboratories
• Aleva Neurotherapeutics SA
• Beijing Pinchi Medical Equipment Co., Ltd.
• Beijing PINS Medical Co., Ltd.
• Boston Scientific
• BrainsWay Ltd.
• DBS Technologies Pty Ltd
• Epi-Minder
• Fisher Wallace Laboratories
• Flow Neuroscience
• Functional Neuromodulation Ltd.
• InBrain Neuroelectronics
• Integer Holdings Corporation
• LivaNova PLC
• Medtronic
• Neo-Bionica
• Neuroelectrics
• NeuroPace, Inc.
• Pulsetto
• Renishaw PLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.